Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Recommendation of “Hold” by Brokerages

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) has earned a consensus rating of “Hold” from the five analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $38.3333.

Several analysts have issued reports on the stock. Weiss Ratings downgraded shares of Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Canaccord Genuity Group assumed coverage on shares of Pharming Group in a research note on Friday, April 10th. They set a “buy” rating and a $37.00 price objective for the company. Wall Street Zen cut shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Zacks Research upgraded Pharming Group from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th.

Hedge Funds Weigh In On Pharming Group

Several hedge funds have recently bought and sold shares of the stock. NewEdge Advisors LLC lifted its position in shares of Pharming Group by 11,310.3% in the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after acquiring an additional 28,615 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Pharming Group during the fourth quarter valued at $360,000. SmartHarvest Portfolios LLC purchased a new stake in Pharming Group during the 4th quarter worth about $224,000. Finally, EverSource Wealth Advisors LLC purchased a new stake in Pharming Group during the 2nd quarter worth about $32,000. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Trading Up 1.6%

NASDAQ:PHAR opened at $13.17 on Friday. Pharming Group has a 52-week low of $9.54 and a 52-week high of $21.34. The company has a quick ratio of 2.06, a current ratio of 2.63 and a debt-to-equity ratio of 0.35. The stock has a fifty day simple moving average of $13.13 and a 200-day simple moving average of $15.42. The company has a market capitalization of $932.17 million, a PE ratio of 82.32 and a beta of -0.04.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.12). Pharming Group had a net margin of 3.30% and a return on equity of 4.64%. The business had revenue of $72.45 million during the quarter, compared to analyst estimates of $92.06 million. On average, equities research analysts expect that Pharming Group will post 0.6 earnings per share for the current fiscal year.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.